BYOOVIZ 10 mg/ml, solution for injection bottle, 0.23 ml + 1 needle
Active ingredients: Ranibizumab
Commercialized according to BDPMDispensing in France: Prescription only
Solution for injectionbottle, 0.23 ml + 1 needleintravitréenne
No current ANSM shortage notice is included
Package details
Original BDPM fields are shown in French.
- Official name
- BYOOVIZ 10 mg/mL, solution injectable
- Pharmaceutical form
- solution injectable
- Route of administration
- intravitréenne
- Presentation description
- 1 flacon en verre de 0,23 mL + 1 aiguille-filtre + 1 aiguille pour injection
- Marketing authorisation holder
- SAMSUNG BIOEPIS NL (PAYS-BAS)
- Reimbursement according to BDPM
- 100 %
- Approval for use in healthcare institutions
- oui
- Commercialization declaration date
- 2 Jan 2026
- Prescription and dispensing conditions
- Prescription only
- List I: prescription-only medicine
- Prescribed by specialists only
- Enhanced ANSM monitoring
- No
BDPM identifiers
CIS
68654266CIP73027804CIP133400930278048Composition in BDPM
| Component | Amount per unit | Source type |
|---|---|---|
| RANIBIZUMABsolution | 10 mg · 1 mL de solution | SA |
Information is based on BDPM data and is for reference only. Consult a doctor before use.
Similar medicines
Similar medicines are listed using the official BDPM catalog. Availability must be checked separately. Consult a doctor or pharmacist before switching medicines.
The current BDPM data does not list similar medicines for this product.